You don’t need to be a geek to get into some of the newest technology for keeping track of your health. I was blown away when I heard about pill bottle caps that will tell  you (or your doctor or your caretakers)  if you’ve forgotten to take your meds…a kazoo that measures the chemistry of the air from your lungs…and a telephone that can assess whether you’re depressed–from the tones of your voice.

These gizmos are the brainchildren of David Rose, an entrepreneur who is now the CEO of Vitality, Inc., in Cambridge.  Rose has also invented bathroom scales that can show whether you’ve lost or gained weight, an umbrella that can sense whether it’s going to rain, and objects that assess air quality.

Rose was one of four panelists who spoke last week at a program sponsored by the Medical Development Group about some astounding new health gadgets, most of which are actually on the market. (MDG is a Boston area organization for individuals involved in the medical device and technology industries). 

Rose focused on the above-mentioned pill bottle “Glo-Caps”, which “sense”  when a patient takes a medication, and, via a wireless Internet connection, show health care professionals, patients or caregivers whether reminders are needed.  

The caps light up, play a melody, and even ring a home phone to remind patients to take their pills.  The caps can send weekly emails to remote caregivers, create accountability with doctors through an adherence report, and automatically refill prescriptions. 

Glo-Caps are not currently available for purchase by individuals, but they are being used by patients enrolled in programs sponsored by certain health insurers and pharmacies.

Panelist Ben Rubin, Co-Founder and Chief Technology officer of Zeo, in Newton, MA, described Zeo’s novel  headset and device that monitor an individual’s REM sleep and factors influencing sleep patterns.  Knowing how well you sleep is important because sleep is closely tied to health conditions like obesity, depression, diabetes and the like, Rubin said. “If you measure it, you can manage it.” 

Zeo’s sleep devices, which cost $250,  connect to  an Internet site. For an additional $100, Zeo provides email advice coaching to help individuals improve their “sleep hygiene.” 

There’s also a  Smart Phone application designed to promote better sleep:  using the Ap, you put your phone under your pillow to measure your movement (and restlessness) during sleep.

Panelists also described glucose monitors that send data to doctors via patients’ Smart Phones and Nike running shoes that measure your steps. At one point, Rose pulled out a keychain that tells him whether he’s met his daily walking goals and whether he’s on track (ha ha) to meet his monthly goals.

Also mentioned  were Internet tools such as a Google Ap to measure flu trends; Healthmedia, through which Johnson & Johnson provides digital coaching for managing stress and chronic disease, Philips Direct, which provides live coaching over email, and various “calorie and other body monitors through which individuals can receive online coaching through gyms.

All of these devices fall under a category moderator David Barash, MD, CEO of Concord [MA] Health Strategies calls “local health monitoring” –meaning that the devices can be used by patients or consumers almost anywhere–rather than just at home or in a hospital,  doctor’s office or lab.

 According to a recent review by my client, Scientia Advisors, “remote health monitoring” devices are the fastest growing category in a booming home health care market. 

The devices are growing in popularity in sync with an aging population, increasing chronic disease, and new Internet technologies, Barash said.

Panelist Frank McGillin, Vice President of Global Marketing for Philips Healthcare, which markets a variety of home monitoring devices, said  remote monitoring  will become increasing important in light of growing health care costs.

Gillin cited government statistics showing that  health care current accounts for 17.6 percent of the  gross domestic product in the US, and that by 2050, half of the population in the developed world will be chronically ill—making traditional medical care  fiscally overwhelming. 

Devorah Klein, PhD, a principal at Continuum, in Newton, MA, who designs devices and evaluates patient adherence to therapy regimes for diabetes, asthma, arthritis, multiple sclerosis and erectile dysfunction, emphasized that  simple designs are key because “many patients are not all that interested” in learning to use devices.

And Barash pointed out that while many consumers may be intrigued by these gizmos, doctors have been slow to embrace them.

 For one thing, with a dearth of clinical trials to assess devices’ effectiveness, insurers are reluctant to reimburse doctors for evaluating the data thus compiled.

For another,  it’s not clear how doctors can manage or assess  potentially large amounts of additional data, or  how data collected for individual conditions can be assessed in relation to data collected elsewhere for other, possibly related, conditions.

–Anita M. Harris

New Cambridge Observer is published by the Harris Communications Group, a  writing  and public relations firm in Cambridge, MA.  All rights reserved.

As an author, former radio and TV producer, and communications consultant, I was excited to read about “Vooks”–a hybrid “literary”  form that merges text, Web and video features–in the New York Times. 

Although most of the highbrows who commented  online were skeptical or negative about new vook ventures by Simon and Schuster and others, I’m thrilled–as I’ve been struggling to cram 4 years worth of my LOL  college diaries into linear form–along with memories buttressed by videotapes and photos of concerts and political demonstrations I was delighted to find  on line.

I’m excited to be  able integrate a myriad of forms that will allow me to share  my experiences and my peers’ with my readers –er–viewers–er  surfers.  Oh, heck.  My audience,  if I can figure out how to find one!

BTW–my book in progress is called Ithaca Diaries, and I’d love for you to suggest possible agents or vublishers.

See my blog on the Times article and commenters  at HarrisComblog.com

Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA. We also publish HarrisComblog.

Having completed an excellent three-evening course on Dreamweaver  just this week at Cambridge Community Television in Central Square,  I urge Cantabridgians to take part in one of the focus groups to be conducted in early October–all related to the Cambridge’s technology future  and the role of Comcast, which, by law, sponsors CCTV, in the community.

Here’s the info–lifted in its entirety, I confess–from an email CCTV sent to me yesterday.

New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA. We also publish Harriscomblog.

Cambridge managing consulting firm Scientia Advisors (my client!) has released a fascinating study about growth in the neurostimulation technology markets. 

Scientia has found that these technologies–electrical devices implanted to stimulate portions of the brain, spinal cord and sacral nerve– are growing at a rate of 16 percent –and are beginning to supplant drugs as the treatment of choice for certain conditions.

The study, described in the August 21 Medical Device Daily and in a press release issued yesterday, suggests that these new technologies have fewer side effects and could help cut health care costs by doing away with the need for lifelong drug regimens. Scientia   recommends that device companies become involved in this growth area.

More at www.Scientiaadv.com or http://blog.harriscom.com.

Anita Harris

New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.

I’m pleased to report that Cambridge Community Television has once again received the Overall Excellence in Public Access Programming Award from the national Alliance for Community Media in its Hometown Video Festival.

 This is the eighth time in CCTV’s twenty-one year history that the station has received this award, recognizing the diversity and quality of CCTV’s programming, as well as its relevance to the Cambridge community.

CCTV competed in the highest budget category, against much larger access centers in major cities throughout the United States. Numerous CCTV producers also received high accolades in the festival:

Project Documentary’s The Dames, about Boston’s roller derby team, placed first in the Sports Entertainment category; teens participating in CCTV’s youth program were also recognized: Josh Washington and William Sheffield for their original teleplay “Homies”, Julie Pan for “King Open Extended Day Program”, Cody Romano for “Dawn”, and Alex Ayabe for his music video “Guarantee”, which he produced at Cambridge Educational Access.

 Laura Asherman also received an Honorable Mention for her video “You Contribute to Global Warming”. Watch some of our finest programming from 2008 in this video! You can also view the full list of winners at http://2009.acmhometown.org/

I’ve taken several excellent courses at CCTV–in Dreamweaver, Excel, and MS Publisher; also on video shooting and editing.  If you join, fees  are nominal–you get $100 worth of courses for $55–less if you put in volunteer time; more if you’re not a Cambridge resident.  It’s a great way to learn about new technologies,  learn television production, produce videos–even host your own TV program. Check it out!

Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA. HarrisCom also publishes www.blog.harriscom.com

As a graduating  PhD, Robert Langer, now Institute Professor at MIT, was having trouble finding work.

As he told the Health Innovators Group of Combined Jewish Philanthropies on Friday, most of his classmates took jobs with oil companies but  he knew that wasn’t for him.  Having helped found an alternative high school in Cambridge, he  applied for 50 or 60 jobs in curriculum development, but no one wrote him back. Then he tried medical schools and hospitals, but “they didn’t write back, either.”  Finally, someone  in his lab told him that someone at Children’s Hospital sometimes hired “unusual people.”

That “someone” was Judah Folkman, who, in 1974,  was beginning to work on angiogenesis, which involved the idea that cutting the blood flow to tumors could halt  their growth.  The possibility  intrigued Langer, who  was hired–but made a rather inauspicious start.

As a post doc, he spent half of his time scraping meat off of cow bones delivered from a South Boston slaughterhouse. He   discovered 200 methods that didn’t work;. He  faced  hostile scientists who told him they didn’t believe anything he said, and,  as time went on,  was denied many patents by officers who were were unwilling to accept his proof.

It took until 2002 for  the first angiogenisis drug to gain FDA approved.  By then, Bob, who wouldn’t take “no” for an answer, was MIT’s most prolific inventor and a University Professor who had helped found many companies and   inspired countless students–who now run departments, labs, and companies of their own.

I’ve known Bob since the 7th grade…and was in the 8th-grade English class  in which, he tells people , he was so shy that he froze during a public speaking exercise, and got an F.  We both went to Cornell, where, he’s told me, he found that he learned more studying on his own (and playing bridge) than going to class.  And I remember sitting in a pizza parlor with him in  1982, watching as he diagrammed  his ideas on a mechanism for “slow release” for pharmaceuticals–on a napkin.

Despite his success, a recent writeup in Nature,  and much  excitement about possible “pharmacies on a chip,”,  a stem cell device to help individuals with spinal cord injuries,  and an adhesive for heart surgery based on the sticky-stuff that allows gekkos to climb up walls, Bob  remains the same old Bob, who sometimes gets  ideas for new devices, materials and methods  from television and magazine magazines.    He’s still down-to-earth, supportive, and even funny.   (Did  you know that the most  surgical devices are invented by doctors who use household materials to fit their operating needs…which is why the “stretchiness” material used in artificial heart is the same stuff used in ladies’ girdles? )

So- for job hunters out there the message is simple but profound. Believe in yourself and your ideas, treat people kindly, and  keep on going.

Great talk, Bob. Once again, bravo.

AMH

New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.

I’m  helping Cambridge Heart and Kogs Communications get out the good news that the company’s non-invasive test, which is administered much like a stress test, on a treadmill, accurately predicts the risk of sudden cardiac arrest–the leading killer in the US.

Here’s today’s release:

Tewksbury, Mass., March 3, 2009 – Cambridge Heart, Inc. (OTCBB-CAMH), today announced the publication of five articles supporting the use of Microvolt T Wave Alternans™ (MTWA) testing in a supplement to the March issue of the Heart Rhythm journal. Featured in the supplement is a comprehensive meta-analysis of 6,000 patients confirming the value of MTWA as a non-invasive marker of risk for sudden cardiac arrest (SCA).

The MTWA test, administered much like a stress test on a treadmill, was developed by Cambridge Heart as a diagnostic tool to help physicians determine a patient’s risk of sudden cardiac arrest — the leading cause of death in the United States.

The meta-analysis, conducted by a group led by Stefan Hohnloser, MD, FHRS, of the JW Goethe University Division of Cardiology in Frankfurt, Germany, assessed 13 MTWA clinical studies involving approximately 6,000 cardiac patients.

“The results demonstrate that MTWA testing is a consistently accurate predictor of sudden cardiac death and cardiac arrest in patients who do not already have implantable cardiac defibrillators (ICDs),” said Dr. Stefan Hohnloser. “These are the patients for whom MTWA testing is intended.”

The meta-analysis authors also conclude that:

· Patients who test negative for MTWA abnormalities are at extremely low risk (0.3%) for SCA in the next 12 months.

· MTWA testing can help doctors guide ICD therapy to appropriate patients and overcome the widespread reluctance of patients and referring physicians to accept ICD therapy.

· In clinical trials, appropriate ICD shocks are an unreliable surrogate endpoint for SCA and can skew results of risk stratification studies.

“This comprehensive analysis confirms the findings of numerous peer-reviewed studies which underscore the important role of MTWA in assessing a patient’s risk of sudden cardiac arrest,” said Ali Haghighi-Mood, PhD, Chief Executive Officer of Cambridge Heart.

The Heart Rhythm supplement also includes:

· A second meta-analysis of MTWA testing in patients with non-ischemic heart disease, authored by Gaetano De Ferrari, MD and Antonio Sanzo, MD of the Department of Cardiology at Fondazione IRCCS Policlinico San Matteo, Pavia Italy. Analyzing eight available trials involving 1,450 patients, the paper indicates that in this population negative MTWA results can help patients and their physicians decide whether ICD therapy may safely be avoided.

· An article by Michael J. Mirro, MD, Medical Director of the Parkview Health System Clinical Research Center in Fort Wayne Indiana, who describes how his center has incorporated MTWA testing into clinical practice to complement other methods for identifying and educating patients about the risk of SCA.

· A review of numerous studies concerning the underlying cellular mechanisms of T-wave alternans. The authors conclude that microvolt T-wave alternans is a marker of cellular changes that make the heart susceptible to sudden cardiac arrest. The review was carried out by Michael Cutler, DO, PhD, and David S. Rosenbaum, MD, of the Heart and Vascular Research Center at the Department of Biomedical Engineering at Case Western Reserve University in Cleveland.

· A review by Navinder Sawhney, MD and Sanjiv Narayan, MD of the University of California at San Diego that underscores the value of MTWA testing in patients who have had heart attacks but do not fall within current guidelines for ICD implantation.

The articles in the supplement can be found on the Heart Rhythm journal website at:

http://www.heartrhythmjournal.com/issues/contents?issue_key=S1547-5271(09)X0006-8

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans measurement technologies including the patented Analytic Spectral Method^® and ultrasensitive disposable electrode sensors. Medicare reimburses the Analytic Spectral Method^® under its National Coverage Policy. Cambridge Heart, founded in 1990, is based in Tewksbury, MA. The company’s Microvolt T-Wave Alternans™ (MTWA) test, developed by Cambridge Heart (OTCBB: CAMH), is based on research originally conducted at the Massachusetts Institute of Technology. http://www.cambridgeheart.com.

Statements contained in this press release are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to achieve broad market acceptance of the Company’s MTWA technology, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company’s target markets, failure to obtain or maintain adequate levels of third-party reimbursement for use of the Company’s MTWA test, customer delays in making final buying decisions, decreased demand for the Company’s products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology and other factors identified in our most recent Annual Report on Form 10‑K/A under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.

The New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.

I’m pleased to announce that Scientia Advisors has launched ScientiaNET,  a “knowledge network” for  health care and the life sciences. ( True,  they are my client, but I AM pleased).

The network now has 10 thousand member/experts and is seeking additional ones.  Members are leading scientists, physicians, practitioners, academics and industry professionals who are  paid their hourly rates to provide Scientia and its clients with analyses, opinions, surveys and consultation on life science tools and technologies, medical devices, diagnostics, biotechnology, pharmaceuticals, functional foods, and regulatory issues.

The member/experts typically consult with business leaders and decision-makers on industry trends and developments, operational problems/solutions, or specific products/services.

If you’d like to become a ScientiaNET member or engage one (or many)   please visit www.scientiaadv.com. 

AMH

Scientia Advisors, based in Cambridge, MA and Palo Alto, CA, is a global management consulting firm specializing in strategic growth and operational strategies  for major and emerging companies in health care and the life sciences.

New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.